Submit supplemental Biologics License Application for the Phase 2B QUILT-2.005 trial
Deadline not yet reached (65 days left)
- Announced
- 4 Aug 2026
- Due
- 31 Dec 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“including a planned 2026 sBLA submission for the Phase 2B QUILT-2.005 trial in BCG-naïve NMIBC carcinoma in situ (with or without papillary disease)”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- sBLA for Phase 2B QUILT-2.005 trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you ImmunityBio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-IBRX-002828 · Corrections policy